Virtual clinical trials now being used to fast-track drug development during coronavirus crisis

Other prominent start-ups in the space include Science 37, a full-service virtual trial platform, and Unlearn.AI, a service that creates digital twins of patients to expand data sets. In April, Unlearn.A1 received $12 million in Series A financing led by 8VC.

The U.S. Food and Drug Administration also helped clear the path to virtual trials in March by issuing guidelines for clinical studies during the pandemic that included “evaluating alternative methods for assessments, like phone contacts or virtual visits, and offering additional safety monitoring for those trial participants who may no longer have access to investigational product or the investigational site.”

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Press

Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Blog

Welcoming Dr. Taylor to Unlearn.AI’s Board of Directors

Press

Unlearn Appoints AstraZeneca’s Chief Medical Officer Ann E. Taylor, M.D. to Board of Directors

Ann E. Taylor, M.D., Chief Medical Officer at AstraZeneca, has joined the Unlearn Board of Directors.
I’m honored to have such an inspirational and experienced leader like Dr. Taylor join our board.
The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.